Atropine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Atropine and local guidelines before prescribing.
Mechanism
Competitive muscarinic antagonist.
Uses
Symptomatic bradycardia, organophosphate and cholinergic poisoning, antimuscarinic premedication.
Dosing
Quick reference (Makindo topics site)
| Main use | Adult dose | Key pearl / caution |
|---|---|---|
| Symptomatic bradycardia | 500 microg IV every 3–5 min (max 3 mg) | May not work in high-grade block; prepare pacing. |
Source: Makindo topics, Emergency Drugs Collection (topic 1479). Editorial draft, not clinically signed off; doses are as written there. Check BNF and local policy before prescribing.
This drug is not covered by a dedicated section of the textbook chapters.
Side effects
Dry mouth, blurred vision, tachycardia, urinary retention, confusion, hot dry skin.
Interactions
Additive antimuscarinic effects with tricyclics and antihistamines.
Contraindications and cautions
Glaucoma (narrow-angle), myasthenia gravis in some settings, obstructive uropathy
Monitoring
ECG, pulse, pupil size
Pregnancy and breastfeeding
Use if needed
Renal and hepatic impairment
No adjustment
Overdose and reversal
Physostigmine rarely; supportive cooling and benzodiazepines
Special advice
May not work in high-grade or infranodal block (prepare pacing); caution in glaucoma and prostatic hypertrophy; in organophosphate poisoning large doses may be needed.